KRAS and neoplasm: For example, SMAD4 inhibits tumor progression initiated by KRAS (G12D) in pancreatic ductal adenocarcinomas (PDAC); in a subset of advanced tumor, intact SMAD4 promotes TGF‐β‐dependent growth and EMT [112].